Literature DB >> 16634342

Evaluating rehabilitation using cost-consequences analysis: an example in Parkinson's disease.

Heather Gage1, Julie Kaye, Charles Owen, Patrick Trend, Derrick Wade.   

Abstract

OBJECTIVE: To use cost-consequences analysis to evaluate rehabilitation, and to discuss some practical limitations.
DESIGN: Case study of a cost-consequences analysis.
SETTING: Day hospital.
SUBJECTS: People with Parkinson's disease without major cognitive loss, and their carers. INTERVENTION: A programme of multidisciplinary rehabilitation, delivered for one day per week over six weeks, and including 2 h of individual therapy (physical, occupational, speech and language, specialist nurse) and group activities on each occasion. COSTS: direct and overhead costs of treatment; participant travel. CONSEQUENCES: patient outcomes (mobility, speech and language, disability, psychological well-being, health-related quality of life); carer outcomes (psychological well-being, health-related quality of life, strain); social service utilization; satisfaction.
RESULTS: In this example the main costs were facility's overheads and hospital-provided transport. The consequences of the intervention were improved immediate outcomes for patients that diminished over four months, discovery of unmet social services need, high satisfaction. No benefits for carers were observed.
CONCLUSION: A cost-consequences analysis provides a clear descriptive summary for decision-makers that is easier to interpret than cost-effectiveness, cost-utility and cost-benefit analysis. It is a useful technique in rehabilitation research where multiple outcomes and several perspectives (health service, patient, carer) are relevant. However limitations remain: it is difficult to capture all consequences because of data deficiencies and long-term effects; evaluations of individual interventions are partial and do not guarantee economic rationality; local studies may not be generalizable; fixed protocols impede the evaluation of alternative service configurations.

Entities:  

Mesh:

Year:  2006        PMID: 16634342     DOI: 10.1191/0269215506cr936oa

Source DB:  PubMed          Journal:  Clin Rehabil        ISSN: 0269-2155            Impact factor:   3.477


  7 in total

1.  Carer preferences in economic evaluation and healthcare decision making.

Authors:  Hareth Al-Janabi; Nikki McCaffrey; Julie Ratcliffe
Journal:  Patient       Date:  2013       Impact factor: 3.883

Review 2.  Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review.

Authors:  Nafsika Afentou; Johan Jarl; Ulf-G Gerdtham; Sanjib Saha
Journal:  Mov Disord Clin Pract       Date:  2019-04-11

3.  Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability.

Authors:  Esther Cubo
Journal:  Clinicoecon Outcomes Res       Date:  2010-09-06

4.  A comparison of specialist rehabilitation and care assistant support with specialist rehabilitation alone and usual care for people with Parkinson's living in the community: study protocol for a randomised controlled trial.

Authors:  Heather Gage; Sharlene Ting; Peter Williams; Karen Bryan; Julie Kaye; Beverly Castleton; Patrick Trend; Derick Wade
Journal:  Trials       Date:  2011-11-23       Impact factor: 2.279

5.  Predicting carer health effects for use in economic evaluation.

Authors:  Hareth Al-Janabi; Andrea Manca; Joanna Coast
Journal:  PLoS One       Date:  2017-09-26       Impact factor: 3.240

6.  Realist evaluation of cancer rehabilitation services in South Wales (REEACaRS): a mixed methods study protocol.

Authors:  Judit Katalin Csontos; Deborah Fitzsimmons; Mari Jones; Wendy M Wilkinson; Joanne Horton; Lisa Love-Gould; Anna Tee; Tessa Watts
Journal:  BMJ Open       Date:  2019-04-23       Impact factor: 2.692

7.  Quality of life among caregivers of people with end-stage kidney disease managed with dialysis or comprehensive conservative care.

Authors:  Karan K Shah; Fliss E M Murtagh; Kevin McGeechan; Susan M Crail; Aine Burns; Rachael L Morton
Journal:  BMC Nephrol       Date:  2020-05-04       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.